glp-1/gip dual agonist lilly Eli Lilly's GIP/GLP-1 Tirzepatide: Lowering Blood Sugar, Weight, And Cardiovascular Risk! - Industry news - News New findings from SURPASS-EARLY: A

For immunofluorescent staining, tissue sections were incubated with anti-insulin antibody (Abcam), followed by a secondary fluorophore-conjugated antibodies (Invitrogen), or with FITC conjugated anti-mouse CD11c (BD Bioscience), or with Cy5 conjugated anti-mouse F4/80 (eBioscience) and counterstained with 4,6-diamidino-2-phenylindole (DAPI) (Sigma)

Pretreatment with GLP-1(2836) reduces infarct size in mice and provides direct GLP-1Rindependent cardioprotection in isolated mouse hearts

Article Google Scholar Gabery, S

Concomitant suppression of inappropriate glucagon secretion from alpha cells further improves glycemic control by reducing hepatic glucose production during fed states [36]

Other options like metformin may be considered in select cases